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Background: Transforming growth factor beta (TGFβ) is upregulated in chronic inflammation, where it plays a key
role in wound healing and promoting fibrosis. However, little is known about the peripheral effects of TGFβ on
nociception.
Methods: We tested the in vitro effects of TGFβ1 on the excitability of dorsal root ganglia (DRG) neurons and the
function of potassium (K) channels. We also studied the effects of TGFβ1 infusion on pain responses to noxious
electrical stimulation in healthy rats as well as the effects of neutralization of TGFβ1 on evoked pain behaviors in a
rat model of chronic pancreatitis.
Results: Exposure to TGFβ1 in vitro increased sensory neuronal excitability, decreased voltage-gated A-type K+
currents (IA) and downregulated expression of the Kv1.4 (KCNA4) gene. Further TGFβ1 infusion into the naïve rat
pancreas in vivo induces hyperalgesia and conversely, neutralization of TGFβ1 attenuates hyperalgesia only in rats
with experimental chronic pancreatitis. Paradoxically, TGFβ1 neutralization in naïve rats results in pancreatic
hyperalgesia.
Conclusions: TGFβ1 is an important and complex modulator of sensory neuronal function in chronic inflammation,
providing a link between fibrosis and nociception and is a potentially novel target for the treatment of persistent
pain associated with chronic pancreatitis.
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Chronic pancreatitisBackground
Sustained/chronic sensitization of sensory neurons,
resulting in pathological pain, can be induced by various
components of the inflammatory milieu including
physico-chemical factors (temperature, acid) as well as a
variety of small molecules, cytokines, growth factors,
other peptides and enzymes that are a hallmark of
chronic inflammation [1]. Transforming growth factor
beta (TGFβ) is also prominently expressed in such* Correspondence: ppasric1@jhmi.edu
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reproduction in any medium, provided the orsituations and plays a key role in wound healing and
promoting fibrosis. TGFβ and other members of its
superfamily including activin and bone morphogenetic
proteins (BMP) are recognized as playing critical roles in
the development, survival and repair of neurons in the
peripheral and central nervous systems (CNS) [2,3].
Intact and injured dorsal root ganglia (DRG) neurons
produce TGFβ and express TGFβ receptors [4,5], and
endogenous TGF potentiates the trophic effect of other
growth factors on DRG neurons [6,7]. Despite this
knowledge, the role of TGFβ on peripheral noccieptor
sensitization remains unknown.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Zhu et al. Molecular Pain 2012, 8:65 Page 2 of 10
http://www.molecularpain.com/content/8/1/65We hypothesized that TGFβ is an important modulator
of peripheral sensory neuronal function and plays a major
role in the pathogenesis of pain in chronic inflammatory
disorders. We tested this hypothesis in chronic pancrea-
titis, as TGFβ is known to be upregulated in the pancreas
in this condition in rodents as well as humans [8,9]. Here
we show that TGFβ1 can directly sensitize nociceptors,
induce pancreatic hyperalgesia and contribute to the
enhanced nocifensive response that accompanies chronic
pancreatitis. These changes are accompanied by a de-
crease in IA voltage-dependent potassium currents and
downregulation of the KCNA4 gene that may encode this
function, providing a possible mechanistic explanation for
these findings.
Results
TGFβ1 sensitizes nociceptor neurons in vitro
TGFβ activation is mediated through two receptors
(TGFβRI and TGFβRII) that work in series: TGFβRII is
necessary for the initial binding of TGF and subsequent
recruitment of the type I receptor and initiation of the
signaling cascade. We confirmed previous reports of the
expression of TGFβ receptors in DRG [5]. TGFβRI and
TGFβRII were co-expressed in all neurons and a sub-
stantial proportion of glia in DRG using immunochemis-
try (Figure 1).TGF RI TGF
TGF RI PGP9.5          
TGF RI 
GFAP                 
RII
Figure 1 TGFβRI expression in dorsal root ganglia neurons was analy
Upper pannel- TGFβRI (green), TGFβRII (red) and a merged image; Middle p
pannel-TGFβRI (green), GFAP (red) and a merged image. (Scale Bar = 75 μmTo assess the effect of TGFβ1 on neuronal excitability,
we added TGFβ1 (10 ng/ml) to rat DRG cultures for
48 hours and then measured the electrophysiological
properties of neurons (ranging in size from 15–30 μm)
using whole-cell patch-clamp recording techniques.
Under current clamp mode, in response to 2 x rheobase
current injections, an approximately two-fold increase in
evoked spikes were observed in the majority of neurons
treated with TGFβ1 (Figure 2a), averaging 2.13 ± 0.52
spikes (n = 16 from 8 rats) as compared with 1.15 ± 0.26
in controls (n = 20 from 6 rats; P < 0.05). Examination of
the time course of the TGFβ1 sensitization showed that
it occurred at 24–48 hours of exposure but not earlier,
suggesting that this effect is not due to direct effects on
the membrane (Figure 2a, right panel). Other measures
of excitability were also examined (Figure 2b): the rest-
ing membrane potential (RMP) was less negative in
TGFβ1 treated neurons (−52.6 ± 2.28 mV; n = 19, 7 rats)
as compared with control neurons ( −60.2 ± 2.45 mV;
n = 19, 6 rats; P = 0.002). The voltage threshold for trig-
gering an action potential was lower, i.e., nearer to the
resting membrane potential in TGFβ1 treated neurons
(−45 ± 14.96 mV; n = 14, 8 rats) as compared with con-
trol (−32.71 ± 3.36 mV; n = 14, 6 rats; P = 0.02). The
rheobase (the minimal current pulse required for trigger-
ing an action potential) was also smaller in neuronsMERGE
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Figure 2 a. Left: Representative tracing of action potentials displayed by DRG neurons in culture after 48 hours of exposure to TGFβ1,
in response to current injections of 1x or 2x rheobase. Middle: Bar graph showing the average number of action potentials evoked by 2x
rheobase current injection after 48 hours of culture with TGFβ1 or control. Right:.Action potential frequency of DRG neurons in cultures increases
with increasing duration of exposure to TGFβ1 (P =0.02 by ANOVA). b. Bar graphs showing electrophysiological changes in cultured DRG neurons
after 48 hours of exposure to TGFβ1. Left: Resting membrane potential (n = 19 in each group); Middle: Voltage threshold for triggering an action
potential (n = 19 in each group); Right: Rheobase (current required to trigger an action potential) (n = 20 in each group). *P <0.05. **P <0.01.
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compared with controls (0.46 ± 0.15 nA; n = 20, 6 rats;
P =0.04).
Analysis of action potentials (AP), as illustrated in Figure 3,
revealed that TGFβ1 resulted in an increase in the AP base
duration (18.97±1.44 ms, n=17 versus 12.7±0.94 ms,
n=19, in controls) as well as in the half -width
(5.89±0.41 ms, n=17 versus 4.73±0.37 ms, n =19 in con-
trols; P=0.04). Action potential shoulder duration obtained
from digital differentiation (dV/dt) was prominently broa-
dened (4.36±0.76 ms n=17 versus 2.26±0.26 in controls,
n=19; P=0.01).
However, the amplitude of action potentials was simi-
lar in both TGFβ1-treated (82.94 ± 4.06 mV; n =17) and
control neurons (72.37 ± 4.56 mV; n = 19; P = 0.1).
Together these changes suggest a marked increase in
membrane excitability in response to TGFβ1 treatment.
TGFβ suppresses A-type potassium currents in sensory
neurons
We have previously determined that changes in
voltage-gated potassium (Kv) currents are important in
contributing to the excitability of DRG neurons in rats
with chronic pancreatitis [10]. We therefore examined
the possibility that TGFβ1 treatment affects Kv currents
in DRG neurons, specifically focusing on the transient
'A-type' current (IA) and the 'sustained delayed rectifiertype' (IK). TGFβ1 treatment resulted in a significant re-
duction in IA density (23.16 ± 4.02 pA/pF, n = 10, 7 rats)
as compared with controls (50.46 ± 12.15 pA/pF, n = 7,
5 rats, P = 0.02) (Figure 4b, middle). We also compared
IA conductance between two groups and observed no
significant differences between TGFβ1 treated neurons
and controls (Figure 4b, bottom). Moreover, TGFβ1
treatment did not result in a significant reduction of IK
density (Figure 4b, top), averaging 96.64 ± 22.93 pA/pF
in TGFβ1 treated neurons (n = 10, 7 rats) versus
70.95 ± 29.28 pA/pF in controls (n = 7, 5 rats; P = 0.5).
The molecular basis of IA is incompletely understood,
with the most commonly implicated Kv subunits being
1.4 (KCNA4) and 4.3 (KCND3) [11,12]. We therefore
investigated the effects of TGFβ1 on the expression of
these genes in sensory neurons using RT-PCR and found
a significant decrease in KCNA4 mRNA levels
(Figure 4c, top); while KCND3 (Kv4.3) mRNA levels
were not significantly different (data not shown). Al-
though the total number of immunopositive DRG cells
did not differ between the treatment and control group
(93% versus 97%), analysis of fluorescent intensity per
cell showed a significant decrease in Kv1.4 fluorescence
in neuronal cultures treated with TGFβ1 (Figure 4c,
middle and bottom). Taken together, these results
suggest that TGFβ1 modulates the regulation of KCNA4
gene expression in individual nociceptors.
Figure 3 Analysis of action potential after incubation with TGFβ1. Top: Left, a representative action potential (AP) tracing (solid line) and
threshold (dotted line) taken from a DRG neuron treated with TGFβ1. The single AP was evoked by a current injection at rheobase of 0.2 nA, and
the parameters were measured for AP amplitude, threshold, Action potential durations at base (APBD) widths at half amplitude (AP ½ HW). The
associated trace is a derivative of AP showing shoulder duration appeared on the falling phase of the AP. Right, AP amplitudes were not different
in the two groups: 72.37 ± 4.5 mV in control (n = 19) and 82.94 mV in TGFβ1 group (n = 17; P = 0.11). Bottom: Left, APBD: controls = 12.7 ± 0.94 ms
(n = 19) and TGFβ1 treated neurons = 18.97 ± 1.44 ms (n = 17). Middle, AP ½ HW: controls = 4.73 ± 0.37 ms (n = 19) and TGFβ1 treated
neurons = 5.89 ± 0.41 ms (n = 17). Right, Shoulder durations: controls = 2.26 ± 0.26 ms (n = 19) and TGFβ1 treated neurons = 4.36 ± 0.76 ms (n = 17).
*P <0.05,**P ≤0.01.
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We first infused TGFβ1 (400 ng in 400 μL) into the pan-
creas of rats and 24 hours later measured the subsequent
behavioral response to noxious electrical stimulation of
the pancreas, an established method for testing nocicep-
tion in this organ [13,14]. Figure 5a shows the pooled
results of two replicate experiments, each of which also
showed a statistically significant change when analyzed
independently. Intrapancreatic TGFβ1 infusion results in
a significant upward shift of the stimulus response curve
(P < 0.0001 for both stimulus-induced response and
TGFβ1 effect by two-way repeated measures ANOVA;
n = 10 in the TGFβ1 group and n= 9 in the vehicle
group). Histopathological examination did not reveal any
differences in pancreatic morphology between the two
groups.
TGFβ1 contributes to pain behavior in a rat model of
chronic pancreatitis
We next assessed the effects of neutralization of TGFβ1
on pain behavior in a rat model of chronic pancreatitis
using a neutralizing antibody which has been shown to
be effective in antagonizing TGFβ1 effects lasting up to
six weeks or more [15]. Control rats were given thesame dose of another antibody against TGFβ1 but with-
out neutralizing properties. Rats underwent testing for
pain behavior in response to electrical stimulation at
baseline and one week after treatment. Figures 5b and c
show the pooled results of two replicate experiments
(each of which also showed a statistically significant
change when analyzed independently). Those receiving
the neutralizing anti-TGFβ1 antibody displayed a signifi-
cant reduction in pain behaviors in response to electrical
stimulation (Figure 5b; two-way repeated measures
ANOVA: stimulus effect, P <0.0001; treatment effect,
P <0.0001; n = 9). Applying a Bonferroni post-hoc test, this
effect is significant at all three intensities of electrical
stimulation. By contrast, the non- neutralizing antibody
had no effect on the responses to electrical stimulation
(Figure 5c; two-way repeated measures ANOVA: stimulus
effect, P = 0.0003; treatment effect, P = 0.70; n = 9).
In a subset of these rats (n = 4 in each group), we also
examined referred somatic hyperalgesia using von Frey
filament (VFF) testing as previously described in this
model [15] (Figures 5d and e). Overall, the response fre-
quencies of rats treated with the neutralizing antibody
were significantly lower compared to pretreatment base-
line, with the stimulus–response curve shifting lower
Figure 4 a. Representative K+ currents in DRG neurons treated with TGFβ1. Step depolarizations from −60 to +30 mV in 5-mV increments
(duration = 400 ms, holding potential = −100 mV) were used to activate all Kv channels (Itotal) in cultured DRG neurons with or without
exposure to TGFβ for 48 hours (left column, top two rows). Manipulating the holding potential to –50 mV with the same depolarization steps
activated most of the sustained Kv channels but not IA channels (middle column, top two rows). Subtraction of IK from Itotal yields IA (right
column, top two rows). The peak I-V curves for IA are shown in the bottom row. b. Quantification of IK (top) and IA (middle) currents in TGFβ1-
treated and control neurons. TGFβ1 treatment resulted in a significant reduction in IA density at +30 mV (28.58 ± 3.958, n = 25 versus 68.67 ± 11.95
n = 17) but not in IK density. The bottom panels shows the normalized conductance (G/V relationship) for IA currents in control (n = 7) and TGFβ1
treated neurons (n = 10). c. Changes in KCNA4 expression in response to TGFβ1. Top: mRNA expression in DRG cultures treated with TGFβ1,
expressed relative to GAPDH mRNA expression. Middle: Representative immunohistochemistry images from control and TGFβ1 treated cultures.
Bottom: Bar graph showing relative intensity of cell fluorescence (averaged per high power field) showing significant decrease after 48 hours of
exposure to TGFβ1 as compared with controls (854.3 ± 84.61, n = 11 fields versus 11348.3 ± 25.47, n = 8 fields). ** P < 0.01; ***P < 0.001.
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P <0.0001; treatment effect, P <0.0001). On the other
hand, rats treated with the non-neutralizing antibody did
not show any change in their response frequencies
(stimulus effect, P < 0.0001; treatment effect, P = 0.84).
Neutralization of TGFβ1 had no significant effect on
histological signs of inflammation in pancreatic speci-
mens. Unexpectedly, by contrast to rats with chronic
pancreatitis, TGF neutralization resulted in hyperalgesia
to electrical stimulation in naïve rats, as shown in
Figure 6 (n = 8, P < 0.0001 for both stimulation and treat-
ment effect), whereas the non-neutralizing antibody had
no effect (n = 8, P <0.0001 for stimulation, P =0.31 for
treatment effect).
Discussion
Ongoing tissue injury and inflammation initiate a cas-
cade of events resulting in peripheral sensitization i.e.
enhancement of the responsiveness of primary afferent
neurons (nociceptors), whose bodies lie in dorsal root
ganglia (DRG) and whose central ends synapse withsecond order neurons in the spinal cord. Sensitized noci-
ceptors display increased spontaneous activity as well as
increased responsiveness to both noxious and non-
noxious stimulation. While post-translational changes in
key ion channels and receptors underlie the immediate/
acute phase of sensitization, sustained/chronic peri-
pheral sensitization is also accompanied by neuroplastic
transcriptional events induced by biologically active
components in the environment.
Although TGFβ is prominent in this milieu and
its receptors are expressed by DRG neurons [5], its par-
ticipation in sensitization of the primary nociceptor
(peripheral sensitization) has received little attention.
There is some evidence that TGF may participate in the
central processing of pain signals. Intrathecal infusion of
anti-TGF β antibody suppresses glial activation and
spinal inflammation and attenuates neuropathic pain
induced by nerve injury in rats [16]. An analgesic role
for TGFβ in the CNS also appears to be indirectly sup-
ported by the attenuation of acute and chronic pain in
mice lacking BAMBI (Bone Morphogenetic Protein and
1.6
5
2.3
6
2.4
4
2.8
3
3.2
2
3.6
1
3.8
4
4.0
8
4.1
7
4.3
1
4.5
6
4.7
4
4.9
3
5.0
7
5.1
8
5.4
6
5.8
8
0
5
10
15 Pre
Post
Pre
Post
Neutralizing antibody
VFF strength
1.6
5
2.3
6
2.4
4
2.8
3
3.2
2
3.6
1
3.8
4
4.0
8
4.1
7
4.3
1
4.5
6
4.7
4
4.9
3
5.0
7
5.1
8
5.4
6
5.8
8
0
5
10
15 Pre
Post
Non-neutralizing antibody
VFF strength
N
um
be
r 
of
 r
es
po
ns
es
N
um
be
r 
of
 r
es
po
ns
es
Non-neutralizing Ab
2 5 10
0
20
40
60
80
100
Pre
Post
mAmA
Neutralizing Ab
2 5 10
0
20
40
60
80
100
2 5 10
0
20
40
60
80
TGFB1
Vehicle
mA
# 
pa
in
 b
eh
av
io
rs
# 
pa
in
 b
eh
av
io
rs
# 
pa
in
 b
eh
av
io
rs
a
b c
d e
Figure 5 a. Behavioral response (“pain behaviors”) to electrical stimulation of the pancreas 16–24 hours after intrapancreatic infusion
of TGFβ1 or vehicle. The graph shows the pooled results of two replicate experiments, each of which showed a statistically significant result
when analyzed independently. Intrapancreatic TGFβ1 results in a significant upward shift of the stimulus response curve (P < 0.0001 for stimulus
and P < 0.01 for TGFβ1 effect by two way ANOVA; n = 10 in the TGFβ1 group and n= 9 in the vehicle group). b, c. Attenuation of pancreatic
hyperalgesia (as measured by the behavioral response to electrical stimulation) in a rat model of chronic pancreatitis by intraperitoneal injection
of a neutralizing antibody to TGFβ1 (left panel) or a non-neutralizing antibody also directed against TGFβ1 (right panel). Baseline responses were
obtained and then repeated one week after administration of the antibody. Treatment with the neutralizing antibody resulted in a marked
attenuation of the behavioral response to electrical stimulation of the pancreas as compared to baseline (P < 0.0001 for both stimulus and
treatment; n = 9) whereas administration of the non-neutralizing antibody resulted in no change in the response (n = 9). d, e. Attenuation of
referred somatic hyperalgesia, as measured by Von Frey filament (VFF) testing. Treatment with the neutralizing antibody resulted in a decrease in
the response frequencies to abdominal wall probing as compared to baseline (P < 0.0001 for both stimulus and treatment) whereas
administration of the non-neutralizing antibody resulted in no change in the response.
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that binds TGFβ and negatively modulates its signaling
[17]. In the CNS, the analgesic effects of TGFβ may be
attributed to the suppression of glial activation and
spinal inflammation, both of which are associated with
pain [18].
On the other hand, TGFβ can also have potentially pro-
nociceptive effects on nociceptors: human TGFβ causes
increased firing of Aplysia nociceptive neurons, a decrease
in their threshold, long-term synaptic facilitation and a re-
duction in synaptic depression [19-22]. Further, activin, amember of the TGF family, induces neuropeptide expres-
sion in nociceptors and sensitization of the vanilloid re-
ceptor, TRPV1 along with hyperalgesia in rats [23-25].
Thus a role for TGFβ in inflammatory pain, particu-
larly with respect to direct effects on nociceptors in per-
ipheral tissues, has yet to be established conclusively. In
this paper we provide the first evidence for a convincing
role of TGFβ in peripheral sensitization, from both
in vitro and in vivo experiments. DRG neurons in cul-
ture show a robust increase in excitablity after incuba-
tion with TGFβ1, with significant changes in several
Figure 6 Effect of TGFβ neutralization on pancreatic nociception in naïve rats. Intraperitoneal injection of a neutralizing antibody to TGFβ1
(left panel) or a non-neutralizing antibody also directed against TGFβ1 (right panel) was administered as described in the text. Nocifensive
behavior was measured in response to to electrical stimulation. The graphs show the pooled results of two replicate experiments, each of which
showed a statistically significant result when analyzed independently. Baseline responses were obtained and then repeated one week after
administration of the antibody. Treatment with the neutralizing antibody resulted in a enhancement of the behavioral response to electrical
stimulation of the pancreas compared to baseline (P < 0.0001 for both stimulus and treatment; n = 8) whereas administration of the non-
neutralizing antibody resulted in no changes in the response (n = 8).
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ent with what we have previously described in this model
of chronic pancreatitis, with changes in resting membrane
potential, decreased rheobase, and increased number of
spontaneous and evoked action potentials [13]. Further,
we found an increase in action potential duration, similar
to what has been reported for cAMP- and capsaicin-
induced broadening of the AP, which was attributed to a
decrease in voltage-gated potassium (Kv) currents [26].
In order to understand the underlying basis for the
changes observed in this study, we focused on the effects
of TGFβ1 on Kv currents, which we have previously
shown to be significantly downregulated in our model of
chronic pancreatitis [10]. We found that TGFβ1 can
cause downregulation in IA currrents, also similar to
what we have previously observed in pancreatic nocicep-
tors of rats with chronic pancreatitis. Further, this
change in current was associated with the downregula-
tion of expression of a specific gene subserving these
currents, KCNA4, but not KCND3, both of which can
encode these currents in neurons [11,12]. KCNA4 may
be the dominant Kv1 alpha subunit expressed in TRPV1
expressing smaller diameter neurons in the DRG [11],
and changes in KCNA4 have been described in other
models of pain including cystitis [27-29]. However,
TGFβ1 may have effects on other ion channels and sig-
naling pathways that may contribute to increased excit-
ability and sensitization, and these posibilities need to be
examined in future studies. Further, given that DRG
cultures contain a mixture of glia and neurons, we cannot
exclude the possibility that some of the effects on neurons
are indirect, and mediated by glia in response to TGFβ1.
Regardless of the in vitro mechanism, TGFβ1 infusion
into the normal pancreas also induces abdominal
hyperalgesia due to pancreatic stimulation. Conversely,
TGFβ1 antagonism can attenuate hypersensitivity and
hyperalgesia in chronic pancreatitis, a painful inflamma-
tory condition. These studies do not imply that TGFβ isthe sole or even dominant contributor to nociceptive
sensitization in chronic pancreatitis, where many other
factors, such as NGF may also play a role [30,31]. Sur-
prisingly, TGFβ antagonism caused hyperalgesia to
noxious stimulation in naïve rats, suggesting that en-
dogenous TGF plays a tonic modulatory effect in noci-
ception signal processing and that the effects of TGF on
nociception are likely to be complex and bimodal, as has
been described for other biological consequences of
TGF neutralization [32]. Thus, under normal physio-
logical conditions, TGFβ may be required for maintain-
ing sensory neurons in a healthy state whereas in
chronic inflammation, excessive levels may cause
sensitization. The physiological role of TGFβ in main-
taining nociceptor sensitivity requires further studies
and these are currently underway in our laboratory.
It also appears that TGFβ may indeed have dual and
seemingly opposing roles in nociception in the periph-
eral versus central nervous systems, similar to what has
been reported for other peptides such as nociceptin [33].
Our studies do not exclude the possibility that TGFβ
may exert effects on other important ion channels in
nociceptors nor do they pinpoint the signaling pathways
involved in the observed changes in excitability. Finally,
isomers other than TGFβ1, used in this study, may have
different effects on nociception. There are at least three
different TGFβ isomers (1, 2 and 3) with varying degrees
of tissue specific expression: all share a common signaling
pathway that involves both the canonical SMAD pathway
as well as non-canonical (e.g. involving MAP kinases)
[34,35]. Further molecular studies to understand the me-
chanism by which TGFβ exerts these effects are underway.
Conclusions
We have shown that TGFβ1 can result in peripheral
sensitization and contribute to the enhanced nociception
that accompanies chronic inflammation. Further,
our results suggest that this effect may involve the
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planation for the increased neuronal excitability. TGFβ1
is therefore an important modulator of peripheral
sensitization of nociceptive neurons. As such, further
understanding of the role of the pathway in nociceptor
neurons may provide insight into new therapeutic tar-
gets for the treatment of such conditions.
Methods
All experiments were approved by the Institutional Animal
Care and Use Committee at Stanford University in accor-
dance with the guidelines of the International Association
for the Study of Pain. Male Sprague–Dawley rats (Harlan,
Indianapolis, IN), weighing between 250-280 g, were used
in the experiments.
Dorsal root ganglia (DRG) neuron culture
After decapitation, thoracic and lumbar DRGs were dis-
sected out and transferred to ice-cold Minimal Essential
Medium (Gibco, Grand Island, NY) supplemented with
penicillin-streptomycin (2X, Gibco). After trimming the
axons and connective tissue, ganglia were transferred into
Hank’s Balanced Salt Solution containing 5 mg/ml collage-
nase (Type II, Worthington, Lakewood, NJ), and incubated
for three hours at 5% CO2-95% O2 at 37°C. A single cell
supension was subsequently obtained by repeated tritu-
ration through flame-polished glass pipettes and centri-
fuged at 50×g for 10 minutes. Single cells were resuspended
in neurobasal media (Gibco) supplemented with albumin
solution (0.7%, Sigma, St. Louis, MO), penicillin-
streptomycin (2X), B27 with retinoic acid (2X, Invitrogen,
Carlsbad, CA), β-mercaptoethanol (0.11 mM, Gibco),
mouse nerve growth factor (40 ng/ml, Promega, Madison,
WI) and L-glutamine (2X, Gibco) and plated onto poly-l-
ornithine (Sigma) coated coverslips.
Recombinant TGFβ1 (Calbiochem, Gibbstown, NJ)
was applied to the culture media in a concentration of
10 ng/ml. During culture in 36.5°C 5% CO2 incubator,
the culture media (with and without TGFβ1) were
refreshed every 24 hours.
Electrophysiology
Whole-cell voltage patch-clamp recordings were con-
ducted at room temperature (22–23°C) on the stage of
an inverted phase contrast microscope (Nikon Inc.,
Melville, NY). The recording pipettes were pulled from
borosilicate glass to give resistances of 2–6 MΩ. Data
were acquired with Digidata interface 1200 series, and
pClamp software version 9.1 (Molecular Devices,
Sunnyvale, California). The concentration in the pi-
pette solution were as follows (in mM): K gluconate
(115), KCl (25), NaCl (5), HEPES (10), CaCl (1),
EGTA (1.12) and ATP-Mg(2), pH was adjusted to
7.3–7.4 using KOH (280–300 mOsm). The cells werebathed in modified Tyrode saline consisting of (in
mM): NaCl (135), KCl (5.4), MgCl2 (1), CaCl2 (2)
NaH2PO4 (0.1) HEPES (10) glucose (10), with pH
adjusted to 7.3-7.4 using NaOH (300–320 mOsm). In
experiments that required eliminating Na+ current,
[Na+]o was substituted by equimolar choline.
Prior to patch clamping a cell, the amplifier (Axopatch
200B, Molecular Devices, Sunnyvale, USA) was zeroed
so that any junction potential was balanced by an offset
potential. High resistance (Gigaohm) seals were formed
between the recording electrode and cell membrane and
ruptured by suction using standard patch clamp record-
ing methods. Action potentials were recorded in mode
of I-clamp after obtaining a stablized membrane poten-
tial setting at I = 0. 2-step current stimulation pulses
were injected for a length of 1.8 sec at 1x and 2x rheo-
base with an interval of 600 ms. Current pulses were
repeated in a range of 0.01 to 1 nA steps until an AP
was elicited. Action potential threshold was determined
upon the voltage extent before upstroke. Currents were
recorded under the mode of V-clamp and the current
signals were recorded to disk for off-line analysis using
pClampfit and Origin 7. Results were expressed as
means ± SE, n = number of cells.
Immunohistochemistry of DRG sections
DRGs (T9–13) were removed and postfixed for 4 hours
in 4% paraformaldehyde and cryoprotected overnight in
30% sucrose in PBS. Tissue was embedded in optimal
cutting temperature (OCT) and 10 μm frozen sections
were prepared. Sections were blocked and permeabilized
for 1 h at room temperature with PBS containing 0.3%
Triton X-100 and 10% normal goat serum and incubated
overnight at 4°C with primary antibodies diluted in PBS
containing 1.5% normal goat serum. The following anti-
bodies were used: mouse monoclonal antibody TGFβR I
(1:100; ab27969), rabbit polyclonal TGFβR II (1:100;
ab66045; abcam, Cambridge, MA, USA), Polyclonal
Rabbit Anti-PGP 9.5 (1:400; Dako), and αGFAP (rabbit
1:400; Dako, Carpinteria, CA). After washing with PBS,
secondary goat antibodies anti-mouse IgG488 and anti-
rabbit IgG 594 (Invitrogen, Carlsbad, CA, U.S.A.) were
added to the preparations at 1:200 dilution. Sections were
rinsed with PBS 15 min ×3 times and viewed under a fluo-
rescent microscope (Nikon Eclipse E600, Japan) with an
excitation wavelength appropriate for 488 and 594.
Immunohistochemistry and quantification of fluorescence
for KCNA4 expression
DRG cultures with and without TGFβ1 treatment at
48 hours were fixed in 4% paraformaldehyde (PFA) for
30 minutes. Nonspecific antibody binding was blocked
by incubation with 8% normal horse serum plus 1%
bovine serum albumin for 1 hour. The preparation was
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(1:200; NeuroMab, UC Davis, CA, U.S.A.) overnight at
4°C plus 1 hour at room temperature. Secondary goat
antibody anti-mouse IgG 488 (Invitrogen, Carlsbad, CA,
U.S.A.) was added to the preparations at 1:200 dilution.
Each step was rinsed with PBS for 15 min × 3 times.
Staining was examined with a fluorescent microscope
(Nikon Eclipse E600, Japan) with an excitation wave-
length appropriate for 488. All procedures were done
under the same conditions including staining and scan-
ning. Quantification of Kv1.4 expression was performed
using the public domain NIH ImageJ program (http://
rsb.info.nih.gov/nih-image/). The area of immunoposi-
tive cells was determined by threshold with subtraction
of background noise and then expressed as mean of
fluorescent intensity per high power field.
RT-PCR of KCNA4 gene expression
RNA was extracted from DRG cultures with and without
TGFβ1 treatment at 48 hours as described above. cDNA
was made from 100 ng of total RNA prior to being pre-
amplified for 14 cycles in the presence of various taq-
man primers obtained from ABI (Foster City, CA). Fold
change was determined by the delta delta Ct method
after normalizing to GAPDH and expressed relative to
the mean value of the control group.
Intrapancreatic infusion of TGFβ1
Under anesthetization with ketamine/xylazine, the peri-
toneum was incised to expose the duodenum and the
duodenal loop was pulled out. The pancreatic duct
entering the duodenum was identified under dissecting
microscope and a small nick was made into the duct. A
30-gauge needle with polyethelene 10 tubing (Becton
Dickinson and Company, Franklin Lakes, NJ) was guided
into the pancreatic duct whilst the common bile duct
was loosely ligated at both ends. 400 μl of a 10% ethanol
in phosphate buffered saline containing 400 ng of TGFβ1
(R&D Systems, Minneapolis, MD) or vehicle alone was
injected into the pancreatic duct. The tubing was carefully
removed and bile flow from the liver into the duodenum
was re-established. A pair of electrodes was carefully
sutured into the pancreatic tissue as described below under
“evaluation of pain behavior”. After removing the tube, the
abdominal cavity was closed with sutures and rats were
allowed to recover. Pain behavior was assessed in both
groups of rats 24 hours post TGFβ1 infusion.
Induction of chronic pancreatitis in rats
The pancreatic duct was accessed as described above
and 0.5 ml of 6 mg/ml solution of trinitrobenzene
sulfonic acid (TNBS), in 10% ethanol in PBS (pH 7.4)
was infused over a period of 2 to 5 minutes. Needle and
tubing were then removed, the abdominal cavity wasclosed with sutures and rats were allowed to recover.
Rats underwent further intervention at three weeks
when a robust chronic pancreatitis has developed, as
described previously by us [13,36].
Evaluation of pain behavior
At the time of surgery for intraductal infusion of TNBS,
a pair of electrodes was attached to the pancreas and
externalized behind the head, as previously described
[13,36], and the rats were allowed to recover. At speci-
fied times rats were given successive applications of
current at 2, 5 and 10 mA for 5 min at a 10-min interval
between stimulation periods. The number of nocifensive
pain behaviors during the stimulation period was mea-
sured. Pain behavioral responses consisted of stretching,
licking of the limbs and abdomen, contraction of ab-
dominal wall muscles and extension of the hind limbs as
previously described [13,36]. All the tests were per-
formed by an observer blinded to the treatment.
Blockade of TGFβ1
Three weeks after infusion of TNBS, we injected a neutral-
izing antibody (MAB 240, R&D Systems, Minneapolis,
MD) in a single dose of 1 mg/kg intraperitoneally to a
group of rats. Control rats received the same dose of
another antibody against TGFβ1 which did not have neu-
tralizing properties (MAB 2401, R&D Systems). At baseline
and one week after the injection, rats underwent testing
for pain behavior. At this dose, the neutralizing antibody
has been shown to be effective in antagonizing TGFβ1
effects up to six weeks or more [15].
Statistical analysis
Results were expressed as means ± SEM, with n being
the number of cells. The paired Student's t-test was used
to evaluate differences between mean values of two
groups. For multiple groups, ANOVA was used. P values
of ≤0.05 were considered to indicate a statistically signifi-
cant difference. IA current conductance was determined
according to the formula G= I/(Vt−Vrev) where G is the
conductance, Vt is the test potential at which current is
measured, and Vrev is the reversal potential.
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